| [1] |
Singavi AK, Harrington AM, Fenske TS. Post-transplant lymphoproliferative disorders[J]. Cancer Treat Res, 2015, 165: 305-327. DOI: 10.1007/978-3-319-13150-4_13.
|
| [2] |
Akar Ozkan E, Ozdemir BH, Deniz EE, et al. Posttransplant lymphoproliferative disorder after liver and kidney transplant[J]. Exp Clin Transplant, 2014, 12(Suppl 1): 142-148.
|
| [3] |
Parker A, Bowles K, Bradley JA, et al. Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients-BCSH and BTS Guidelines[J]. Br J Haematol, 2010, 149(5): 675-692. DOI: 10.1111/j.1365-2141.2010.08161.x.
|
| [4] |
Kremers WK, Devarbhavi HC, Wiesner RH, et al. Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival[J]. Am J Transplant, 2006, 6(5 Pt 1): 1017-1024.
|
| [5] |
Caillard S, Lelong C, Pessione F, et al. Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French Registry[J]. Am J Transplant, 2006, 6(11): 2735-2742. doi: 10.1111/ajt.2006.6.issue-11
|
| [6] |
Taylor AL, Marcus R, Bradley JA. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation[J]. Crit Rev Oncol Hematol, 2005, 56(1): 155-167. doi: 10.1016/j.critrevonc.2005.03.015
|
| [7] |
Faull RJ, Hollett P, Mcdonald SP. Lymphoproliferative disease after renal transplantation in Australia and New Zealand[J]. Transplantation, 2005, 80(2): 193-197. doi: 10.1097/01.TP.0000165098.49658.F3
|
| [8] |
Dharnidharka VR, Ho PL, Stablein DM, et al. Mycophenolate, tacrolimus and post-transplant lymphoproliferative disorder: a report of the North American Pediatric Renal Transplant Cooperative Study[J]. Pediatr Transplant, 2002, 6(5): 396-399. doi: 10.1034/j.1399-3046.2002.00021.x
|
| [9] |
Boubenider S, Hiesse C, Goupy C, et al. Incidence and consequences of post-transplantation lymphoproliferative disorders[J]. J Nephrol, 1997, 10(3): 136-145.
|
| [10] |
Engels EA, Pfeiffer RM, Fraumeni JF Jr, et al. Spectrum of cancer risk among US solid organ transplant recipients[J]. JAMA, 2011, 306(17): 1891-1901. DOI: 10.1001/jama.2011.1592.
|
| [11] |
Lee KF, Tsai YT, Lin CY, et al. Cancer incidence among heart, kidney, and liver transplant recipients in Taiwan[J]. PLoS One, 2016, 11(5): e0155602. DOI: 10.1371/journal.pone.0155602.
|
| [12] |
Evens AM, Roy R, Sterrenberg D, et al. Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy[J]. Curr Oncol Rep, 2010, 12(6): 383-394. DOI: 10.1007/s11912-010-0132-1.
|
| [13] |
Knight JS, Tsodikov A, Cibrik DM, et al. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center[J]. J Clin Oncol, 2009, 27(20): 3354-3362. DOI: 10.1200/JCO.2008.20.0857.
|
| [14] |
Nelson BP, Nalesnik MA, Bahler DW, et al. Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity?[J]. Am J Surg Pathol, 2000, 24(3): 375-385. doi: 10.1097/00000478-200003000-00006
|
| [15] |
Paya CV, Fung JJ, Nalesnik MA, et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting[J]. Transplantation, 1999, 68(10): 1517-1525. doi: 10.1097/00007890-199911270-00015
|
| [16] |
Ellis D, Jaffe R, Green M, et al. Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression[J]. Transplantation, 1999, 68(7): 997-1003. doi: 10.1097/00007890-199910150-00017
|
| [17] |
Walker RC, Paya CV, Marshall WF, et al. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations[J]. J Heart Lung Transplant, 1995, 14(2): 214-221.
|
| [18] |
Dharnidharka VR, Sullivan EK, Stablein DM, et al. Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS)[J]. Transplantation, 2001, 71(8): 1065-1068. doi: 10.1097/00007890-200104270-00010
|
| [19] |
Mcdonald RA, Smith JM, Ho M, et al. Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids[J]. Am J Transplant, 2008, 8(5): 984-989. DOI: 10.1111/j.1600-6143.2008.02167.x.
|
| [20] |
Dotti G, Fiocchi R, Motta T, et al. Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant[J]. Transplantation, 2000, 69(5): 827-833. https://www.researchgate.net/publication/232103602_Epstein-Barr_Virus-Negative_Lymphoproliferative_Disorders_in_Long-Term_Survivors_After_Heart_Kidney_and_Liver_Transplant1
|
| [21] |
Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients[J]. Lancet, 1993, 342(8886/8887): 1514-1516. https://www.researchgate.net/publication/15296132_Incidence_of_non-Hodgkin_lymphoma_in_kidney_and_heart_transplant_recipients
|
| [22] |
Jagadeesh D, Woda BA, Draper J, et al. Post transplant lymphoproliferative disorders: risk, classification, and therapeutic recommendations[J]. Curr Treat Options Oncol, 2012, 13(1): 122-136. DOI: 10.1007/s11864-011-0177-x.
|
| [23] |
Opelz G, Naujokat C, Daniel V, et al. Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients[J]. Transplantation, 2006, 81(9): 1227-1233. doi: 10.1097/01.tp.0000219817.18049.36
|
| [24] |
Caillard S, Dharnidharka V, Agodoa L, et al. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression[J]. Transplantation, 2005, 80(9): 1233-1243. doi: 10.1097/01.tp.0000179639.98338.39
|
| [25] |
Opelz G, Döhler B. Lymphomas after solid organ transplantation: a collaborative transplant study report[J]. Am J Transplant, 2004, 4(2): 222-230. doi: 10.1046/j.1600-6143.2003.00325.x
|
| [26] |
Younes BS, Mcdiarmid SV, Martin MG, et al. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients[J]. Transplantation, 2000, 70(1): 94-99. https://www.researchgate.net/publication/12399545_The_effect_of_immunosuppression_on_posttransplant_lymphoproliferative_disease_in_pediatric_transplant_patients
|
| [27] |
Reshef R, Luskin MR, Kamoun M, et al. Association of HLA polymorphisms with post-transplant lymphoproliferative disorder in solid-organ transplant recipients[J]. Am J Transplant, 2011, 11(4): 817-825. DOI: 10.1111/j.1600-6143.2011.03454.x.
|
| [28] |
Pourfarziani V, Einollahi B, Taheri S, et al. Associations of human leukocyte antigen (HLA) haplotypes with risk of developing lymphoproliferative disorders after renal transplantation[J]. Ann Transplant, 2007, 12(4): 16-22. https://www.researchgate.net/publication/5507253_Associations_of_Human_Leukocyte_Antigen_HLA_haplotypes_with_risk_of_developing_lymphoproliferative_disorders_after_renal_transplantation
|
| [29] |
Subklewe M, Marquis R, Choquet S, et al. Association of human leukocyte antigen haplotypes with posttransplant lymphoproliferative disease after solid organ transplantation[J]. Transplantation, 2006, 82(8): 1093-1100. doi: 10.1097/01.tp.0000235889.05171.12
|
| [30] |
Stern M, Opelz G, Dohler B, et al. Natural killer-cell receptor polymorphisms and posttransplantation non-Hodgkin lymphoma[J]. Blood, 2010, 115(19): 3960-3965. DOI: 10.1182/blood-2009-10-250134.
|
| [31] |
Babel N, Vergopoulos A, Trappe RU, et al. Evidence for genetic susceptibility towards development of posttransplant lymphoproliferative disorder in solid organ recipients[J]. Transplantation, 2007, 84(3): 387-391. doi: 10.1097/01.tp.0000269617.60751.c4
|
| [32] |
Thomas RV, Mcaulay K, Higgins C, et al. Interferon gamma (IFN-gamma) polymorphism in posttransplantation lymphoproliferative disease[J]. Blood, 2005, 106(4): 1502-1503. doi: 10.1182/blood-2005-03-1279
|
| [33] |
Cockfield SM. Identifying the patient at risk for post-transplant lymphoproliferative disorder[J]. Transpl Infect Dis, 2001, 3(2): 70-78. doi: 10.1034/j.1399-3062.2001.003002070.x
|
| [34] |
Kapelushnik J, Ariad S, Benharroch D, et al. Post renal transplantation human herpesvirus 8-associated lymphoproliferative disorder and Kaposi's sarcoma[J]. Br J Haematol, 2001, 113(2): 425-428. doi: 10.1046/j.1365-2141.2001.02740.x
|
| [35] |
Buda A, Caforio A, Calabrese F, et al. Lymphoproliferative disorders in heart transplant recipients: role of hepatitis C virus (HCV) and Epstein-Barr virus (EBV) infection[J]. Transpl Int, 2000, 13 (Suppl 1): S402-S405. https://www.researchgate.net/profile/Andrea_Buda/publication/12216192_Lymphoproliferative_disorders_in_heart_transplant_recipients_Role_of_hepatitis_C_virus_HCV_and_Epstein-Barr_virus_EBV_infection/links/541864930cf25ebee9881b0c.pdf
|
| [36] |
Dockrell DH, Strickler JG, Paya CV. Epstein-Barr virus-induced T cell lymphoma in solid organ transplant recipients[J]. Clin Infect Dis, 1998, 26(1): 180-182. doi: 10.1086/cid.1998.26.issue-1
|
| [37] |
Kwong YL, Lam CC, Chan TM. Post-transplantation lymphoproliferative disease of natural killer cell lineage: a clinicopathological and molecular analysis[J]. Br J Haematol, 2000, 110(1): 197-202. doi: 10.1046/j.1365-2141.2000.02138.x
|
| [38] |
Buell JF, Gross TG, Hanaway MJ, et al. Posttransplant lymphoproliferative disorder: significance of central nervous system involvement[J]. Transplant Proc, 2005, 37(2): 954-955. doi: 10.1016/j.transproceed.2004.12.130
|
| [39] |
Wagner HJ, Wessel M, Jabs W, et al. Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction[J]. Transplantation, 2001, 72(6): 1012-1019. doi: 10.1097/00007890-200109270-00006
|
| [40] |
Stevens SJ, Verschuuren EA, Pronk I, et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients[J]. Blood, 2001, 97(5): 1165-1171. doi: 10.1182/blood.V97.5.1165
|
| [41] |
Green M, Bueno J, Rowe D, et al. Predictive negative value of persistent low Epstein-Barr virus viral load after intestinal transplantation in children[J]. Transplantation, 2000, 70(4): 593-596. doi: 10.1097/00007890-200008270-00010
|
| [42] |
Lee TC, Savoldo B, Rooney CM, et al. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients[J]. Am J Transplant, 2005, 5(9): 2222-2228. doi: 10.1111/ajt.2005.5.issue-9
|
| [43] |
Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy[J]. N Engl J Med, 2006, 354(5): 496-507. doi: 10.1056/NEJMra050276
|
| [44] |
Parker A, Bowles K, Bradley JA, et al. Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients-BCSH and BTS Guidelines[J]. Br J Haematol, 2010, 149(5): 693-705. DOI: 10.1111/j.1365-2141.2010.08160.x.
|
| [45] |
Tsai DE, Hardy CL, Tomaszewski JE, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients[J]. Transplantation, 2001, 71(8): 1076-1088. doi: 10.1097/00007890-200104270-00012
|
| [46] |
Reshef R, Vardhanabhuti S, Luskin MR, et al. Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder (bigstar)[J]. Am J Transplant, 2011, 11(2): 336-347. DOI: 10.1111/j.1600-6143.2010.03387.x.
|
| [47] |
Evens AM, David KA, Helenowski I, et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era[J]. J Clin Oncol, 2010, 28(6): 1038-1046. DOI: 10.1200/JCO.2009.25.4961.
|
| [48] |
Elstrom RL, Andreadis C, Aqui NA, et al. Treatment of PTLD with rituximab or chemotherapy[J]. Am J Transplant, 2006, 6(3): 569-576. doi: 10.1111/j.1600-6143.2005.01211.x
|
| [49] |
Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study[J]. Blood, 2006, 107(8): 3053-3057. doi: 10.1182/blood-2005-01-0377
|
| [50] |
Oertel SH, Verschuuren E, Reinke P, et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD)[J]. Am J Transplant, 2005, 5(12): 2901-2906. doi: 10.1111/j.1600-6143.2005.01098.x
|
| [51] |
Jain AB, Marcos A, Pokharna R, et al. Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center[J]. Transplantation, 2005, 80(12): 1692-1698. doi: 10.1097/01.tp.0000185570.41571.df
|
| [52] |
Choquet S, Oertel S, Leblond V, et al. Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution[J]. Ann Hematol, 2007, 86(8): 599-607. doi: 10.1007/s00277-007-0298-2
|
| [53] |
González-Barca E, Domingo-Domenech E, Capote FJ, et al. Prospective phase Ⅱ trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease[J]. Haematologica, 2007, 92(11): 1489-1494. doi: 10.3324/haematol.11360
|
| [54] |
Trappe R, Oertel S, Leblond V, et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial[J]. Lancet Oncol, 2012, 13(2): 196-206. DOI: 10.1016/S1470-2045(11)70300-X.
|
| [55] |
Zimmermann H, Trappe RU. Therapeutic options in post-transplant lymphoproliferative disorders[J]. Ther Adv Hematol, 2011, 2(6): 393-407. DOI: 10.1177/2040620711412417.
|
| [56] |
Ralf UT, Petra R, Ruth N, et al. Interim analysis of the largest prospective trial to date in adult CD20-positive post-transplant lymphoproliferative disorder (PTLD): introducing risk-stratified sequential treatment (RSST)[J]. J Clin Oncol, 2012, 30(15_suppl): 8030. http://meetinglibrary.asco.org/content/70087?media=vm&poster=1
|
| [57] |
Perrine SP, Hermine O, Small T, et al. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies[J]. Blood, 2007, 109(6): 2571-2578. doi: 10.1182/blood-2006-01-024703
|
| [58] |
Haque T, Wilkie GM, Jones MM, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial[J]. Blood, 2007, 110(4): 1123-1131. doi: 10.1182/blood-2006-12-063008
|
| [59] |
Kirk AD, Cherikh WS, Ring M, et al. Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab[J]. Am J Transplant, 2007, 7(11): 2619-2625. doi: 10.1111/ajt.2007.7.issue-11
|
| [60] |
Davis CL. Interferon and cytotoxic chemotherapy for the treatment of post-transplant lymphoproliferative disorder[J]. Transpl Infect Dis, 2001, 3(2): 108-118. doi: 10.1034/j.1399-3062.2001.003002108.x
|
WeChat Subscription Account
Wechat Service Account
Supported by:
Beijing Renhe Information Technology Co. Ltd
DownLoad: